A recent study reveals that people who discontinue new weight-loss injections like semaglutide or tirzepatide may regain reduced body mass at a significantly accelerated pace than those who end traditional diet and exercise programs.
Published data in a major medical journal shows that while obese people often shed a large proportion of their total mass while on the medication, the mass comes back at an average rate of 0.8 kg per month upon discontinuation.
"People buying such drugs must be aware of the potential of quick weight regain when the medication ends," stated researcher Dr. Susan Jebb.
Such speed of recovery means a reversion to starting mass within about one and a half years.
Weighing Therapies
The study, which reviewed 37 of studies involving over 9,000 of patients, compared the effects of GLP-1 agonists with older methods.
Researchers note that people who shed pounds through lifestyle changes alone typically see a more gradual creep back—around 100 grams monthly—once they finish.
Explaining the Quick Regain
Doctors propose the mechanism of the jabs is key to understanding the heightened regain.
The injections copy a body's own chemical called glucagon-like peptide-1, which controls feelings of fullness.
"Long-term administration of the hormone concentrations far above than normal might result in the system to produce less of its own natural GLP-1, and could reduce sensitivity to its effects," said Dr. Adam Collins, a nutrition specialist.
"Discontinuation of this medication means appetite is uncontrolled, making binge eating much more probable."
An Ongoing Condition?
The NHS recommend the injections for individuals with weight-linked health risks, alongside prescribed diet and exercise modifications.
Many experts say that, due to the significant potential of relapse, the therapy should be considered life-long.
This view is reinforced by pharmaceutical companies, who state that the results "highlight the persistent character of excess weight," comparing it to managing conditions like diabetes.
User Accounts
People who have stopped the jabs describe a intense resurgence of appetite.
"I experienced something that goes on and you're instantly extremely hungry," recalled an individual.
The struggle is exacerbated if patients have not developed permanent lifestyle or habit changes during therapy.
Significant Interest
Survey data suggest that a significant number of people in the UK have tried weight-loss jabs in the last 12 months, with demand being substantial.
- Use is more common among females than men.
- The 40s and 50s age group shows the greatest usage rates.
- A large proportion access the drugs through private prescriptions rather than the NHS.
Ultimately, experts caution that while GLP-1 drugs are effective tools for weight loss, they are not a magic cure and long-term success relies on combined behavioural support.
